Results 61 to 70 of about 756 (179)
Cp*Co(III)‐catalyzed C–H functionalization of bioactive heterocyclic motifs
Bulletin of the Korean Chemical Society, Volume 46, Issue 6, Page 622-635, June 2025.Directed carbon–hydrogen bond functionalization of biologically active scaffolds is attractive as it enables the selective modification of sophisticated structures, enhancing the efficiency of drug development by adopting diverse functional groups. This review summarizes recent advances in cobalt‐catalyzed C–H functionalizations of bioactive motifs ...
Yeongmi Park +3 more
wiley +1 more source
Osteoporosis and Sarcopenia, 2019 Objectives: We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a poor response ...
Mikio Kamimura +6 more
doaj +1 more source
Pharmaceuticals, 2020 Medication-related osteonecrosis of the jaw (MRONJ) is associated with many drugs, including bisphosphonates (BPs). BPs are associated with atypical femoral fractures and osteonecrosis of the external auditory canal.
Shinya Toriumi +2 more
doaj +1 more source
Antisenescence therapies for age‐related bone loss: Target factors, medicines, biomedical materials
Clinical and Translational Medicine, Volume 15, Issue 6, June 2025.With extended lifespans causing population aging, bone aging has become a worldwide issue. Cellular senescence in the bone microenvironment causes bone degeneration and dysfunction. This review summarises targets in cellular senescence and bone aging while detailing potential therapeutic strategies, including novel medicines and innovative biomedical ...
Qiyue Zhu +6 more
wiley +1 more source
Osteoporosis and Sarcopenia, 2019 Objectives: Increasing bone mineral density (BMD) to reduce fracture risk is a primary goal of osteoporosis treatment. This prospective, observational study evaluates the effects of monthly minodronate (MIN; 50 mg) with or without eldecalcitol (ELD ...
Takako Suzuki +2 more
doaj +1 more source
European Journal of Organic Chemistry, Volume 28, Issue 8, February 24, 2025.There are continuous efforts to improve total syntheses of natural products, particularly their sustainability, such as developing effective chiral pool approaches relying on a wide spectrum of natural chirons, including (−)‐sclareol as one of the most useful natural chirons.
Ayyoub Selka +5 more
wiley +1 more source
Journal of Orthopaedic Surgery and Research, 2020 Background Osteoporosis is a metabolic bone disease. Bisphosphonate (BP) and eldecalcitol (ELD) are two clinical first-line drugs for osteoporosis patients. However, the effect of ELD + BP vs. BP alone on osteoporosis treatment is still unclear.
Zaoqian Zheng, Jinyu Luo
doaj +1 more source
Stem Cell Research & Therapy, 2022 Background The incidence of diabetic osteoporosis is increasing. This article evaluates the effect of combination treatment with the hypoglycemic drug exendin-4 (Ex-4) and the vitamin D analog eldecalcitol (ED-71) on improving diabetic osteoporosis and ...
Yupu Lu +6 more
doaj +1 more source
Case Reports in Orthopedics, Volume 2025, Issue 1, 2025.Background Subtrochanteric fracture is a recognized complication following osteosynthesis for femoral neck fractures, typically occurring within 1–2 months postoperatively. At the time of onset, incomplete healing of the femoral neck fracture often results in a complex fracture configuration that poses challenges for management.
Hirokazu Takai +8 more
wiley +1 more source
, 2022 The document indicates the SPIRIT checklist for the protocol: a randomized study of the efficacy of ibandronic acid plus eldecalcitol in patients with gastric cancer after gastrectomy: A comparative study of different routes of administration of ...
Hisaki Aiba (12989435)
core +1 more source